Table 1.
Demographic and Clinical Characteristics by Treatment Group
| Q‐ter + creatine (n = 35) | Placebo (n = 32) | P Value | |
|---|---|---|---|
| Age (y) | 72 ± 6 | 71 ± 6 | 0.38 |
| Male gender (n, %) | 29 (82.9) | 28 (87.5) | 0.75 |
| Weight (kg) | 73 ± 13 | 76 ± 12 | 0.34 |
| Height (m) | 1.69 ± 0.06 | 1.79 ± 0.07 | 0.65 |
| Current smokers (n, %) | 5 (14.3) | 4 (12.5) | 0.32 |
| COPD (n, %) | 3 (8.6) | 4 (12.5) | 0.70 |
| DM (n, %) | 13 (37.1) | 12 (37.5) | 1.00 |
| Dyslipidemia (n, %) | 19 (54.3) | 14 (53.7) | 0.20 |
| HT (n, %) | 19 (54.3) | 20 (62.5) | 0.62 |
| MI (n, %) | 24 (68.6) | 21 (65.6) | 0.50 |
| Myocardial revascularization (n, %) | |||
| PCI | 14 (40.0) | 9 (28.1) | 0.49 |
| CABG | 12 (34.3) | 11 (34.4) | |
| PAD (n, %) | 5 (14.3) | 7 (21.9) | 0.53 |
| Stroke (n, %) | 1 (2.9) | 2 (6.3) | 0.60 |
| AF (n, %) | 5 (14.3) | 8 (25.0) | 0.36 |
| CHF etiology (n, %) | |||
| ischemic | 29 (82.9) | 24 (75.0) | 0.55 |
| nonischemic | 6 (17.1) | 8 (25.0) | |
| LVEF (%) | 30 ± 4 | 31 ± 4 | 0.37 |
| NYHA class (n, %) | |||
| II | 31 (88.6) | 30 (93.8) | 0.68 |
| III | 4 (11.4) | 2 (6.3) | |
| Medical therapy (n, %) | |||
| ACEI/anti‐ATII | 32 (91.4) | 31 (96.9) | 0.62 |
| Antialdosteronic agents | 11 (31.4) | 18 (56.3) | 0.05 |
| β‐Blocking agents | 23 (65.7) | 24 (75.0) | 0.44 |
| Digoxin | 16 (45.7) | 12 (37.5) | 0.62 |
| Furosemide | 25 (71.4) | 29 (90.6) | 0.07 |
| Furosemide dose (mg/d)a | 25.0 (10.7–25.0) | 37.5 (25.0–75.0) | 0.07 |
| Total work capacity (kg·m) | 2118 ± 1118 | 2013 ± 936 | 0.68 |
| Peak VO2 (mL/kg/min) | 13.4 ± 2.3 | 12.8 ± 2.6 | 0.29 |
| SIP total score | 8.3 ± 7.4 | 9.0 ± 5.6 | 0.67 |
| SIP physical score | 6.5 ± 5.1 | 6.7 ± 6.3 | 0.86 |
| SIP psychosocial score | 7.8 ± 7.0 | 10.0 ± 8.6 | 0.25 |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; anti‐ATII, angiotensin II type 1 receptor antagonist; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HT, hypertension; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; PAD, peripheral artery disease; PCI, percutaneous coronary intervention (primary or elective angioplasty); Q‐ter, coenzyme Q10 terclatrate; SIP, Sickness Impact Profile; VO2, oxygen consumption.
a
Furosemide dose represents median daily dose of furosemide (33rd–66th percentile).